Compare AGM & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AGM | GENB |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | 212 | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | N/A | N/A |
| Metric | AGM | GENB |
|---|---|---|
| Price | $183.62 | $15.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $215.00 | $23.20 |
| AVG Volume (30 Days) | 118.8K | ★ 894.4K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.97 | N/A |
| Revenue Next Year | $12.21 | $16.58 |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $136.57 | $11.00 |
| 52 Week High | $210.64 | $16.75 |
| Indicator | AGM | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 57.87 | 62.75 |
| Support Level | $169.65 | $11.73 |
| Resistance Level | $185.70 | $16.75 |
| Average True Range (ATR) | 5.45 | 1.14 |
| MACD | 0.06 | 0.24 |
| Stochastic Oscillator | 73.40 | 93.01 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.